Aptevo Therapeutics (NASDAQ:APVO) Now Covered by StockNews.com

Equities researchers at StockNews.com began coverage on shares of Aptevo Therapeutics (NASDAQ:APVOGet Free Report) in a report released on Tuesday. The firm set a “hold” rating on the biotechnology company’s stock.

Aptevo Therapeutics Stock Performance

Shares of NASDAQ:APVO opened at $3.80 on Tuesday. The company’s 50 day moving average price is $5.87 and its two-hundred day moving average price is $8.79. Aptevo Therapeutics has a 12-month low of $3.62 and a 12-month high of $91.96.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in APVO. Sabby Management LLC acquired a new stake in shares of Aptevo Therapeutics during the 3rd quarter worth approximately $440,000. Armistice Capital LLC acquired a new stake in shares of Aptevo Therapeutics during the 3rd quarter worth approximately $408,000. Citadel Advisors LLC acquired a new stake in shares of Aptevo Therapeutics during the 4th quarter worth approximately $47,000. Cantor Fitzgerald L. P. boosted its position in shares of Aptevo Therapeutics by 14.8% during the 2nd quarter. Cantor Fitzgerald L. P. now owns 251,122 shares of the biotechnology company’s stock worth $367,000 after acquiring an additional 32,422 shares in the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Aptevo Therapeutics during the 1st quarter worth approximately $152,000. Institutional investors and hedge funds own 8.06% of the company’s stock.

About Aptevo Therapeutics

(Get Free Report)

Aptevo Therapeutics Inc, a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and.

Featured Stories

Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.